Garenoxacin Treatment of Experimental Endocarditis Caused by Viridans Group Streptococci
|
|
- Gerald Richards
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2006, p Vol. 50, No /06/$ doi: /aac Copyright 2006, American Society for Microbiology. All Rights Reserved. Garenoxacin Treatment of Experimental Endocarditis Caused by Viridans Group Streptococci Paloma Anguita-Alonso, 1 Mark S. Rouse, 1 Kerryl E. Piper, 1 James M. Steckelberg, 1 and Robin Patel 1,2 * Division of Infectious Diseases, Department of Medicine, 1 and Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, 2 Mayo Clinic College of Medicine, Rochester, Minnesota Received 23 June 2005/Returned for modification 3 October 2005/Accepted 27 January 2006 The activity of garenoxacin was compared to that of levofloxacin or penicillin in a rabbit model of Streptococcus mitis group (penicillin MIC, g/ml) and Streptococcus sanguinis group (penicillin MIC, 0.25 g/ml) endocarditis. Garenoxacin and levofloxacin had MICs of and 0.5 g/ml, respectively, for both study isolates. Rabbits with catheter-induced aortic valve endocarditis were given no treatment, penicillin at IU/8 h intramuscularly, garenoxacin at 20 mg/kg of body weight/12 h intravenously, or levofloxacin at 40 mg/kg/12 h intravenously. For both isolates tested, garenoxacin area under the curve (AUC)/MIC and maximum concentration of drug in serum (C max )/MIC ratios were 368 and 91, respectively. Rabbits were sacrificed after 3 days of treatment; cardiac valve vegetations were aseptically removed and quantitatively cultured. For S. mitis group experimental endocarditis, all studied antimicrobial agents were more active than no treatment (P < 0.001), whereas for S. sanguinis group endocarditis, no studied antimicrobial agents were more active than no treatment. We conclude that AUC/MIC and C max /MIC ratios may not predict activity of some quinolones in experimental viridans group endocarditis and that garenoxacin and levofloxacin may not be ideal choices for serious infections caused by some quinolone-susceptible viridans group streptococci. Viridans group streptococci are commensal bacterial flora that are common causes of native valve endocarditis. Viridans group streptococcal endocarditis is a severe infection associated with high morbidity and mortality. Its treatment includes administration of a prolonged course of a bactericidal antimicrobial regimen, typically administered intravenously (1). The long-term care and costs associated with such therapy and the emergence of viridans group streptococci relatively resistant to beta-lactams (8, 25) have led to a search for new antimicrobials for the treatment (and prophylaxis) of viridans group streptococcal endocarditis. Combination therapy including an aminoglycoside has been advocated by the American Heart Association to treat penicillin-intermediate and -resistant viridans group streptococcal strains causing infective endocarditis (1) and to shorten therapy for endocarditis caused by penicillin-susceptible viridans group streptococcal strains (26). However, aminoglycoside side effects limit the use of such approaches (16). Quinolones are generally considered bactericidal antimicrobial agents with high oral bioavailability and good penetration into valvular vegetations (12), making them theoretically suitable for treatment of infective endocarditis. Quinolones in combination with rifampin have been used to treat right-sided Staphylococcus aureus endocarditis (10). However, in the case of viridans group streptococci, quinolones have, in some cases, failed as treatments for experimental endocarditis (4, 22), and emergence of quinolone-resistant viridans group streptococci in bone marrow transplant patients receiving prophylaxis with levofloxacin has been reported (24). Garenoxacin is a new * Corresponding author. Mailing address: Division of Infectious Diseases, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN Phone: (507) Fax: (507) quinolone with enhanced potency against gram-positive bacteria, including penicillin-resistant Streptococcus spp. and Staphylococcus spp. (3, 17), that could potentially address the abovementioned limitations of quinolones. Experimental infective endocarditis is a rigorous test of bactericidal activity of antimicrobial agents (9). We designed a rabbit model of infective endocarditis to determine the in vivo activity of garenoxacin in the treatment of viridans group streptococcal endocarditis in comparison to penicillin and levofloxacin. (This work was presented in part at the 43rd [14 to 17 September 2003, Chicago, Ill.] and 44th [30 October to 2 November 2004, Washington, D.C.] Interscience Conference on Antimicrobial Agents and Chemotherapy.) MATERIALS AND METHODS Microorganisms. Thirty viridans group streptococci (nine Streptococcus sanguinis group isolates, nine Streptococcus mitis group isolates, seven Streptococcus mutans group isolates, three Streptococcus salivarius group isolates, and two S. anginosus group isolates) were studied in vitro; all isolates were associated with human infective endocarditis. Organisms were reidentified (23) and classified according to Facklam criteria (15). Two isolates were selected for in vivo studies: IDRL-4600, a penicillin-susceptible S. mitis group isolate, and IDRL-4954, a penicillin-intermediate S. sanguinis group isolate. Both were ciprofloxacin susceptible according to Clinical and Laboratory Standard Institute (CLSI) interpretive standards (7), and both were previously studied in experimental rabbit endocarditis in our laboratory (22). Antimicrobial agents. Ceftriaxone, levofloxacin (for in vitro studies), and vancomycin were purchased from Sigma-Aldrich, Inc. (St. Louis, MO). Ciprofloxacin was purchased from USP (Rockville, MD). Garenoxacin was provided by Bristol-Myers Squibb (Syracuse, N.Y.). Levofloxacin (for in vivo studies) was purchased from Ortho-McNeil Pharmaceutical, Inc. (Raritan, N.J.). Penicillin was purchased from Monarch Pharmaceuticals, Inc. (Bristol, TN). Antimicrobial susceptibility testing. MICs and minimum bactericidal concentrations (MBCs) were determined by broth microdilution following CLSI guidelines (5, 6). Time-kill studies. Time-kill studies were performed by inoculating an overnight culture of bacteria (final concentration, 10 5 to 10 6 CFU/ml) into flasks 1263
2 1264 ANGUITA-ALONSO ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. MICs and MBCs of the study antimicrobials for the two isolates studied in vivo Antimicrobial agent MIC/MBC ( g/ml) ratio S. mitis group S. sanguinis group Garenoxacin 0.125/ /2 Levofloxacin 0.5/ /4 Penicillin 0.125/ /1 Ciprofloxacin 0.5/1 0.5/8 Vancomycin 1/1 1/ 128 containing Mueller Hinton broth supplemented with 2% lysed horse blood in a final volume of 25 ml. Immediately after inoculation, the antimicrobial agent was added in doubling concentrations to each flask at final concentrations ranging from to 16 g/ml. Samples were removed from the flasks just before the addition of antimicrobial agent and after 6 and 24 h of incubation at 37 C in 5% CO 2. One-hundred microliters of serial dilutions was plated on blood agar plates for quantitative culture. A bactericidal effect was defined as a3log 10 CFU/ml reduction of the initial inoculum. Vegetation induction and colonization. Aortic valve vegetations were induced in New Zealand White rabbits by insertion of a polyethylene catheter across the aortic valve via the right carotid artery, as previously described (22). Bacterial endocarditis was induced 24 h after catheter placement by intravenous bacterial challenge with 1 ml of 10 6 to 10 8 CFU of viridans group streptococci. Twentyfour hours later, a blood culture was obtained to confirm the presence of endocarditis. Animals with negative blood cultures were excluded from the study. Pharmacokinetic studies. Serum antimicrobial concentrations were determined in five healthy animals at 30 min and 1, 2, 4, 6, 12, and 24 h after administration of a single dose of the study antimicrobial agents. Serum concentrations were determined in triplicate by microbiologic assay. Bioassays were performed on Mueller- Hinton agar seeded with Klebsiella pneumoniae ATCC as the indicator organism for garenoxacin and levofloxacin and with Micrococcus luteus ATCC 9341 for penicillin. Plates were incubated for 20 h at 37 C in room air for quinolones and at 30 C in room air for penicillin. The standard curve was determined using pooled rabbit serum. Using this method, the unbound fraction of the antimicrobial agent was measured. Pharmacokinetic parameters were calculated with Origin version 6.0 (Microcal Software, Inc., Northhampton, MA). Treatment groups. One-hundred twenty-four rabbits with viridans group streptococcal endocarditis were assigned to one of four different treatment regimens (16 per group): (i) Control (no treatment); (ii) garenoxacin at 20 mg/kg of body weight/12 h intravenously; (iii) levofloxacin at 40 mg/kg/12 h intravenously; and (iv) penicillin at IU/8 h intramuscularly. Treatment was started 24 h after bacterial challenge and lasted for 3 days. Therapeutic monitoring of animals treated with garenoxacin, levofloxacin, or penicillin was performed on blood collected 30 min after administration of the first dose of antimicrobial agent on the second day of treatment. Twelve hours after administration of the last dose of the antimicrobial agent, the animals were sacrificed with 100 mg/kg of intravenously administered pentobarbital. The chest cavity was opened, the heart was excised, and vegetations were aseptically removed, weighed, and homogenized in 2 ml of Todd-Hewitt broth in a Stomacher 80 (Tekman Co., Cincinnati, Ohio). The homogenate was quantitatively cultured. Serial 10-fold dilutions in Todd-Hewitt broth were plated on blood agar plates (0.1-ml aliquot per plate) and incubated for 48 h at 37 C in 5% CO 2. Results of quantitative cultures were expressed as log 10 CFU per gram of valve vegetation. Animals that died before completing 3 days of treatment were excluded from statistical analysis. Detection of emergence of antimicrobial resistance. MIC testing with the same antimicrobial agent administered for treatment was performed on bacteria recovered from aortic valve vegetations. Identification of quinolone resistance-determining region (QRDR) mutations. Isolates studied in vivo were tested (before treatment) for QRDR mutations. DNA was prepared for amplification from cells grown in Todd-Hewitt broth overnight by alkaline wash as previously described (18). PCR amplification of gyra and parc was performed in a total reaction volume of 50 l, as previously described (19). DNA sequencing was performed by ABI PRISM Big Dye Terminator cycle sequencing with the ABI PRISM 377 automated DNA sequencer (Applied Biosystems). Sequence data were analyzed using Sequencher (GeneCodes Inc., Ann Arbor, MI). Codon positions 81 and 85 of gyra and 79 and 83 of parc were analyzed for mutations in comparison with previously published QRDR sequences of viridans group streptococci. Statistical analysis. Differences in means of log 10 CFU per gram of vegetation for all groups were analyzed by one-way analysis of variance. A Tukey-Kramer post hoc range test was used to determine which means differed. Differences in mortality between treatment groups were compared using the Fisher s exact test. MICs between treatments were compared by a Wilcoxon signed-rank test. All tests were two tailed. Significance was defined as P RESULTS In vitro susceptibility testing and time-kill studies. The 90% minimum inhibitory concentrations (MIC 90 ) were 0.125, 1, 0.25, and 2 g/ml for garenoxacin, levofloxacin, penicillin, and vancomycin, respectively; the 90% minimum bactericidal concentrations (MBC 90 ) were 2, 128, 1, and 128 g/ml for garenoxacin, levofloxacin, penicillin, and vancomycin, respectively, for the 30 study isolates. Among the isolates studied, garenoxacin showed lower MIC 90, MBC 90, MIC, and MBC ranges than levofloxacin (P ). FIG. 1. Garenoxacin time-kill curves. A. S. mitis group garenoxacin time-kill curves. A bactericidal effect was observed with 0.5 g/ml (i.e., four times the MIC). B. S. sanguinis group garenoxacin time-kill curves. A bactericidal effect was observed with 0.5 g/ml (i.e., four times the MIC).
3 VOL. 50, 2006 GARENOXACIN TREATMENT OF STREPTOCOCCAL ENDOCARDITIS 1265 FIG. 2. Penicillin time-kill curves. A. S. mitis group penicillin timekill curves. A bactericidal effect was observed with 0.25 g/ml (i.e., two times the MIC). B. S. sanguinis group penicillin time-kill curves. A bactericidal effect was observed with 16 g/ml (i.e., 64 times MIC). Antimicrobial susceptibilities of the isolates studied in vivo are summarized in Table 1. A bactericidal effect was observed in time-kill studies with 0.5 g/ml garenoxacin (4 times the MIC) for both strains; 2 g/ml levofloxacin (4 times the MIC) for both strains; 4 g/ml (8 times the MIC) and 8 g/ml (16 times the MIC) ciprofloxacin for the S. mitis group and the S. sanguinis group isolates, respectively; and 0.25 g/ml (2 times the MIC) and 16 g/ml (64 times the MIC) penicillin for the S. mitis group and the S. sanguinis group isolates, respectively (Fig. 1 and 2). Presence of QRDR mutations. No QRDR mutations were detected in the isolates studied in vivo. Pharmacokinetic studies. Table 2 summarizes pharmacokinetic parameters and the pharmacodynamic index for both strains studied in vivo. Time above MIC was 100% for all antimicrobial groups studied. Whereas levofloxacin showed greater area under the curve (AUC) and maximum concentration of drug in serum (C max ) values than garenoxacin, garenoxacin AUC/MIC, AUC/ MBC, C max /MIC, and C max /MBC ratios were greater than the respective values for levofloxacin. In vivo results. Results of treatment are summarized in Table 3 and Fig. 3. Mean 30-min antimicrobial serum concentrations monitored during treatment were 25, 19, and 41 g/ml, for penicillin, garenoxacin, and levofloxacin, respectively, in the group infected with the S. mitis group isolate and 26, 18, and 37 g/ml for penicillin, garenoxacin, and levofloxacin, respectively, in the group infected with the S. sanguinis group isolate. Antimicrobial concentrations measured in infected animals were higher than those assessed in healthy animals after a single dose. No differences were found in antimicrobial levels between the two groups (P 0.7 for penicillin and levofloxacin; P 0.1 for garenoxacin). Six animals died before the end of treatment, four with levofloxacin-treated S. mitis group endocarditis and one each with garenoxacin- and levofloxacintreated S. sanguinis group endocarditis (P 0.1). For S. mitis group experimental endocarditis, all three antimicrobial agents studied were more active than was no treatment (P 0.001). There were no significant differences between results of treatment with garenoxacin and levofloxacin. For S. sanguinis group experimental endocarditis, no antimicrobial agent tested was more active than no treatment. No emergence of resistance was detected. DISCUSSION In our experimental rabbit model, trovafloxacin had previously failed as a treatment of viridans group streptococcal endocarditis (22). Furthermore, levofloxacin was relatively ineffective in a rabbit model of viridans group streptococcal endocarditis (4). Given the reported improved activity of garenoxacin against viridans group streptococci both in vitro and in an experimental rat model of experimental endocarditis (13), we designed the present study to test garenoxacin in our model of ciprofloxacin-susceptible viridans group streptococcal endocarditis. While garenoxacin did show in vitro activity TABLE 2. Pharmacokinetic parameters and pharmacodynamic indices for the isolates studied in vivo Antimicrobial agent Isolate group (MIC/MBC) Halflife (h) AUC ( g h/ml) C max ( g/ml) AUC/MIC AUC/MBC C max /MIC C max /MBC Garenoxacin S. mitis (0.125/0.25) S. sanguinis (0.125/2) Levofloxacin S. mitis (0.5/0.5) S. sanguinis (0.5/4) Time above MIC (%) Time above MBC (%) Penicillin S. mitis (0.125/0.25) S. sanguinis (0.25/1)
4 1266 ANGUITA-ALONSO ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Treatment results of vegetation for each treatment group and viridans group streptococcus isolate Isolate Treatment (dosage) No. of animals b Vegetation titer, means SD (log 10 CFU/g) S. mitis group (penicillin susceptible) No treatment Penicillin ( IU t.i.d.) Garenoxacin (20 mg/kg b.i.d.) Levofloxacin (40 mg/kg b.i.d.) S. sanguinis group (penicillin nonsusceptible) No treatment Penicillin ( IU t.i.d.) Garenoxacin (20 mg/kg b.i.d.) Levofloxacin (40 mg/kg b.i.d.) a b.i.d., twice a day; t.i.d., three times a day. b Each group initially consisted of 16 animals; animals that died before the end of treatment were excluded from statistical analysis. FIG. 3. Results of treatment of viridans group streptococcal experimental endocarditis. A. S. mitis group isolate. B. S. sanguinis group isolate. against the isolates studied, in vivo activity was demonstrated in endocarditis caused by a penicillin-susceptible S. mitis group isolate but not a penicillin-intermediate S. sanguinis group isolate. These results are similar to our prior results with trovafloxacin. Although newer quinolones have been reported to be active in the treatment of endocarditis (11, 13, 14, 21), based on our present and prior studies (22) quinolone activity in viridans group streptococcal endocarditis appears to depend on characteristics of the strain causing the disease beyond MICs. Entenza et al. proposed that antimicrobial activity in endocarditis may depend on the ability of the agent to achieve bactericidal concentrations inside vegetations. In their study, sparfloxacin was slower than ceftriaxone to achieve bactericidal concentrations in vegetations, potentially explaining differences between the activity of quinolones and beta-lactams in the 3-day treatment model (11). To the best of our knowledge, cardiac valvular penetration of levofloxacin and garenoxacin has not been defined. In our study, quinolone activity in viridans group streptococcal endocarditis was isolate dependent and independent of MICs, suggesting that factors other than cardiac valvular penetration may be important. We hypothesize that lack of activity of study antimicrobial agents in S. sanguinis group endocarditis is related to the isolate being relatively tolerant to these agents, as suggested by the high MBC/MIC ratios. On the other hand, other strain-specific factors such as glycocalyx formation may influence antimicrobial penetration into vegetations and consequently activity in this model. The time-kill studies demonstrate that a bactericidal effect occurred with penicillin concentrations twice the MIC for the S. mitis group strain and 64 times the MIC for the S. sanguinis group strain. Time-kill studies may predict penicillin treatment failure of S. sanguinis group endocarditis. Some differences between strains were observed in ciprofloxacin time-kill studies where bactericidal concentrations were 8 and 16 times the MICs for S. mitis group and S. sanguinis group, respectively; however, no differences were found for the other study quinolones. In vitro tests were performed with a lower inoculum than occurs in vivo in vegetations (20). The presence of high titers of organisms in vegetations may explain why conventional susceptibility tests do not predict in vivo activity. When we performed garenoxacin and penicillin time-kill studies with an inoculum of 10 7 CFU/ml, no bactericidal effect was ob-
5 VOL. 50, 2006 GARENOXACIN TREATMENT OF STREPTOCOCCAL ENDOCARDITIS 1267 served with antimicrobial concentrations ranging from to 16 g/ml for the S. sanguinis group isolate and a bactericidal effect occurred at 8 g/ml for the S. mitis group isolate (data not shown). Microbiological assay was the method chosen to measure the free fraction of the antimicrobial agents studied. Pooled rabbit serum was used to prepare standard concentrations. Other methods may not yield directly comparable results. Nevertheless, the pharmacodynamic indices for garenoxacin and levofloxacin were adequate based on cutoffs proposed defined by Andes et al. for successful treatment of experimental endocarditis (i.e., C max /MIC greater than 8, AUC/MIC greater than 100, and time above MIC being 100%, depending on the compound) (2). Based on failure of these criteria in our study, we speculate that pharmacodynamic indices predictive of in vivo activity in strains with high MBC/MIC ratios may be those related to MBC and not to MIC (i.e., AUC/MBC, C max /MBC, and/or time above MBC, depending on the compound). This hypothesis would also explain findings reported in previous studies with trovafloxacin (22). In our opinion, this issue deserves further study, since in our study 6 out of 30 viridans group streptococci isolated from patients with endocarditis had garenoxacin MBCs at or above that of the S. sanguinis group isolate studied in vivo. Our findings, along with the emergence of viridans group streptococci resistant to quinolones during quinolone prophylaxis (24), suggest that levofloxacin and garenoxacin may not be ideal for treatment or prophylaxis of viridans group streptococcal infections. In summary, the present study shows in vitro activity of garenoxacin against clinical viridans group streptococcal isolates. However, MICs did not predict in vivo quinolone activity in experimental S. sanguinis group endocarditis. Possibly, AUC/MBC and/or C max /MBC are better predictors of in vivo quinolone activity in viridans group streptococcal endocarditis, since they may better reflect antimicrobial tolerance. ACKNOWLEDGMENTS We acknowledge financial support provided by Brystol-Myers Squibb Company Pharmaceutical Research Institute and a grant from the Instituto de Salud Carlos III, Spanish Ministry of Health (to P.A.-A.). REFERENCES 1. American College of Cardiology/American Heart Association, Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease) ACC/AHA guidelines for the management of patients with valvular heart disease. J. Am. Coll. Cardiol. 32: Andes, D. R., and W. A. Craig Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin. Infect. Dis. 27: Bassetti, M., L. M. Dembry, P. A. Farrel, D. A. Callan, and V. T. Andriole Antimicrobial activities of BMS compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob. Agents Chemother. 46: Chambers, H. F., Q. Xiang, L. Liu, L. Chow, and C. Hackbarth Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob. Agents Chemother. 43: Clinical and Laboratory Standards Institute Methods for determining bactericidal activity of antimicrobial agents, 1st ed. Approved standard M26-A. Clinical and Laboratory Standards Institute, Wayne, Pa. 6. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7 A6. Clinical and Laboratory Standards Institute, Wayne, Pa. 7. Clinical and Laboratory Standards Institute MIC testing. Supplemental tables M100 S14 (M7). Clinical and Laboratory Standards Institute, Wayne, Pa. 8. Doern, G. V., M. J. Ferraro, A. B. Brueggemann, and K. L. Ruoff Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40: Durack, D. T., and R. G. Petersdorf Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens. J. Clin. Investig. 52: Dworkin, R. J., B. L. Lee, M. A. Sande, and H. F. Chambers Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet ii: Entenza, J. M., M. Blatter, M. P. Glauser, and P. Moreillon Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 38: Entenza, J. M., I. Caldelari, M. P. Glauser, and P. Moreillon Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. J. Antimicrob. Chemother. 44: Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. Antimicrob. Agents Chemother. 48: Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41: Facklam, R What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin. Microbiol. Rev. 15: Francioli, P., W. Ruch, and D. Stamboulian Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin. Infect. Dis. 21: Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS Antimicrob. Agents Chemother. 44: Hall, L., K. A. Doerr, S. L. Wohlfiel, and G. D. Roberts Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J. Clin. Microbiol. 41: Janoir, C., V. Zeller, M. D. Kitzis, N. J. Moreau, and L. Gutmann High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parc and gyra. Antimicrob. Agents Chemother. 40: Le, T., and A. S. Bayer Combination antibiotic therapy for infective endocarditis. Clin. Infect. Dis. 36: Levine, D. P., H. P. Holley, I. Eiseman, P. Willcox, and K. Tack Clinafloxacin for the treatment of bacterial endocarditis. Clin. Infect. Dis. 38: Piper, K. E., M. S. Rouse, K. L. Ronningen, J. M. Steckelberg, W. R. Wilson, and R. Patel Trovafloxacin treatment of viridans group streptococcus experimental endocarditis. Antimicrob. Agents Chemother. 44: Prabhu, R. M., K. E. Piper, L. M. Baddour, J. M. Steckelberg, W. R. Wilson, and R. Patel Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to Antimicrob. Agents Chemother. 48: Razonable, R. R., M. R. Litzow, Y. Khaliq, K. E. Piper, M. S. Rouse, and R. Patel Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin. Infect. Dis. 34: Tuohy, M., and J. A. Washington Antimicrobial susceptibility of viridans group streptococci. Diagn. Microbiol. Infect. Dis. 29: Wilson, W. R., R. L. Thompson, C. J. Wilkowske, J. A. Washington, Jr., E. R. Giuliani, and J. E. Geraci Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. JAMA 245:
Natural History of Aortic Valve Endocarditis in Rats
INFECTION AND IMMUNITY, JUlY 192, p. 127-131 19-9567/2/7127-5$2./ Vol. 37, No. 1 Natural History of Aortic Valve Endocarditis in Rats ERIC HtRAIEF, MICHEL P. GLAUSER,* AND LAWRENCE R. FREEDMANt Division
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationExperimental Endocarditis Caused by Streptococcus sanguis:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1981, p. 1-14 66-484/81/71-5$2./ Vol. 2, No. 1 Experimental Endocarditis Caused by Streptococcus sanguis: Single and Combined Antibiotic Therapy MARIA V. VICENTE,
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationSteven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationNew guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson
Journal of Antimicrobial Chemotherapy (1998) 42, 292 296 New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis JAC D. C. Shanson Microbiology Department,
More informationAntibiotic treatment of streptococcal and enterococcal endocarditis: an overview
European Heart Journal (1995) 16 {Supplement B), 75-79 Antibiotic treatment of streptococcal and enterococcal endocarditis: an overview P. FRANCIOLI Division of Hospital Preventative Medicine and Department
More informationEfficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae Strains in a rabbit meningitis model.
AAC Accepts, published online ahead of print on 3 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00285-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 1 2 Efficacy
More informationDetermination of MIC & MBC
1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight
More informationStreptococcus mitis. 11). Reports by Home and Tomasz (11) indicated. that of nine S. sanguis strains tested, all were
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1983, P. 67-73 0066-4804/83/010067-07$02.00/0 Copyright C 1983, American Society for Microbiology Vol. 23, No. 1 Penicillin Therapy of Experimental Endocarditis
More informationRifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1980, p. 658-662 0066-4804/80/04-0658/05$02.00/0 Vol. 17, No. 14 Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination
More informationEndocardite infectieuse
Endocardite infectieuse 1. Raccourcir le traitement: jusqu où? 2. Proposer un traitement ambulatoire: à partir de quand? Endocardite infectieuse A B 90 P = 0.014 20 P = 0.0005 % infective endocarditis
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationMONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS:
MONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS: Application to Estimation of MIC Breakpoints Paul G. Ambrose, Pharm.D. Director, Division of Infectious Diseases, Cognigen Corporation; Adjunct
More informationReceived 21 April 1997/Returned for modification 30 June 1997/Accepted 28 August 1997
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1997, p. 3258 3263 Vol. 35, No. 12 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Comparison of Agar Dilution, Broth Microdilution, E-Test,
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationDaptomycin versus vancomycin in the treatment of methicillin-resistant. Staphylococcus aureus meningitis in experimental rabbit model.
AAC Accepts, published online ahead of print on 14 January 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01996-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Daptomycin
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationStreptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin
2009 21 1) 1, 2) 1, 2) 1) 1) 2) 1) 1) 1) 1) 1) 1, 2) 1) 2) 20 2 29 21 1 14 Streptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin (STFX), DX619 S. pneumoniae S. pneumoniae 60
More informationEvaluation of Antibacterial Effect of Odor Eliminating Compounds
Evaluation of Antibacterial Effect of Odor Eliminating Compounds Yuan Zeng, Bingyu Li, Anwar Kalalah, Sang-Jin Suh, and S.S. Ditchkoff Summary Antibiotic activity of ten commercially available odor eliminating
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationEndocarditis in Rats
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1987, p. 139-143 0066-4804/87/020139-05$02.00/0 Copyright C) 1987, American Society for Microbiology Vol. 31, No. 2 Continuous-Infusion Ampicillin Therapy of
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationAAC Accepts, published online ahead of print on 19 March 2007 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 19 March 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01000-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSitafloxacin activity against Helicobacter pylori including isolates with gyra. Key words: Helicobacter pylori, sitafloxacin, antimicrobial activity,
AAC Accepts, published online ahead of print on 20 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01552-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationStreptococcus sanguis Endocarditis in Rabbits
ANTIMICROBIAL AGNTS AND CHMOTHRAPY, Feb. 1984, p. 263-267 0066-4804/84/020263-05$02.00/O Copyright 1984, American Society for Microbiology Vol. 25, No. 2 Role of Granulocytes in the Prevention and Therapy
More informationOUTLINE Laboratory Detection and Reporting of Streptococcus agalactiae
OUTLINE Laboratory Detection and Reporting of Streptococcus agalactiae I. Importance of prenatal screening strategies II. Past approaches Erik Munson Clinical Microbiology Wheaton Franciscan Laboratory
More informationLaboratory Detection and Reporting of Streptococcus agalactiae
Laboratory Detection and Reporting of Streptococcus agalactiae Erik Munson Clinical Microbiology Wheaton Franciscan Laboratory Milwaukee, Wisconsin The presenter states no conflict of interest and has
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationReceived 26 June 1995/Returned for modification 15 September 1995/Accepted 5 February 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1996, p. 941 946 Vol. 40, No. 4 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Amoxicillin Dose-Effect Relationship with Streptococcus
More informationEffect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni
Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni J. Lin & M. Ensminger Department of Animal Science, The University of Tennessee, Knoxville,
More informationDepartment of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; 2
Pathogens 2015, 4, 599-605; doi:10.3390/pathogens4030599 Article OPEN ACCESS pathogens ISSN 2076-0817 www.mdpi.com/journal/pathogens Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for
More informationEarly oral switch for antibiotic treatment of infective endocarditis
AEPEI: Association pour l Etude et la Prévention des Endocardites Infectieuses Early oral switch for antibiotic treatment of infective endocarditis Prof. Pierre Tattevin Infectious Diseases & ICU, INSERM
More informationLoyola ecommons. Loyola University Chicago. Virginia Long Loyola University Chicago. Recommended Citation
Loyola University Chicago Loyola ecommons Master's Theses Theses and Dissertations 2014 Identification of Clinical Markers That Predict the Outcomes of Methicillin-Resistant Staphylococcus Aureus Infections
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationAntibiotic Treatment of Adults With Infective Endocarditis Due to Streptococci, Enterococci, Staphylococci, and HACEK Microorganisms
Antibiotic Treatment of Adults With Infective Endocarditis Due to Streptococci, Enterococci, Staphylococci, and HACEK Microorganisms Walter R. Wilson, MD; Adolf W. Karchmer, MD; Adnan S. Dajani, MD; Kathryn
More informationDaniel C. DeSimone, MD Assistant Professor of Medicine
Daniel C. DeSimone, MD Assistant Professor of Medicine Faculty photo will be placed here Desimone.Daniel@mayo.edu 2015 MFMER 3543652-1 Infective Endocarditis Mayo School of Continuous Professional Development
More informationBacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis
Journal of Antimicrobial Chemotherapy (2003) 52, 820 825 DOI: 10.1093/jac/dkg440 Advance Access publication 30 September 2003 Bacteriological outcome of versus single-agent treatment for staphylococcal
More informationSpectrum of vancomycin and susceptibility testing
Spectrum of vancomycin and susceptibility testing Olivier Denis Service de Microbiologie Laboratoire de bactériologie Service de Microbiologie Hôpital Erasme Glycopeptides Vancomycin 1958 < Amycolatopsis
More informationGroup B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,.
Group B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,. 12-10-2017 Group B streptococci are uniformly sensitive to penicillin
More informationInfluence of Water Diuresis on Antimicrobial
Influence of Water Diuresis on Antimicrobial Treatment of Enterococcal Pyelonephritis SANDRA P. LEVISON and DONALD KAYE From the Department of Medicine, The Medical College of Pennsylvania, Philadelphia,
More informationVancomycin Rationale for the EUCAST clinical breakpoints, version June 2010
Vancomycin Rationale for the EUCAST clinical breakpoints, version 2.1 17 June 2010 Introduction The glycopeptides are a class of agents composed of amino acid residues and attached sugars. Glycopeptides
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationActivities of Ertapenem, a New Long-Acting Carbapenem, against Penicillin-Sensitive or -Resistant Pneumococci in Experimental Meningitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1943 1947 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1943 1947.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationInfective endocarditis (IE) By Assis. Prof. Nader Alaridah MD, PhD
Infective endocarditis (IE) By Assis. Prof. Nader Alaridah MD, PhD Infective endocarditis (IE) is an inflammation of the endocardium.. inner of the heart muscle & the epithelial lining of heart valves.
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationIncreasing Genetic Relatedness of Ciprofloxacin-Resistant Streptococcus pneumoniae Isolated in Canada from 1997 to 2005
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2008, p. 1190 1194 Vol. 52, No. 3 0066-4804/08/$08.00 0 doi:10.1128/aac.01260-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Increasing
More informationBiological Consulting Services
Biological Consulting Services of North Florida/ Inc. May 13, 2009 Aphex BioCleanse Systems, Inc. Dear Sirs, We have completed antimicrobial efficacy study on the supplied Multi-Purpose Solution. The testing
More informationACCEPTED ANTIPNEUMOCOCCAL ACTIVITY OF LBM415 COMPARED TO OTHER AGENTS. KLAUDIA KOSOWSKA-SHICK KIM L. CREDITO GLENN A. PANKUCH BONIFACIO DEWASSE
AAC Accepts, published online ahead of print on 20 November 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01150-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationThe activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
Journal of Antimicrobial Chemotherapy (984) 4, Suppl. B, 39-43 The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
More informationExperimental Staphylococcus epidermidis Endocarditis
INFECTION AND IMMUNITY, Sept. 1977, p. 504-509 Copyright 1977 American Society for Microbiology Vol. 17, No. 3 Printed in U.S.A. Effect of Warfarin on the Induction and Course of Experimental Staphylococcus
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and
AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationThis is a repository copy of Antibiotic prophylaxis of endocarditis: a NICE mess.
This is a repository copy of Antibiotic prophylaxis of endocarditis: a NICE mess. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/96643/ Version: Accepted Version Article:
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationDr Babak Tamizi far MD. Assistant Professor Of Internal Medicine Al-Zahra Hospital Isfahan University Of Medical Sciences
Dr Babak Tamizi far MD. Assistant Professor Of Internal Medicine Al-Zahra Hospital Isfahan University Of Medical Sciences ١ ٢ ٣ A 57-year-old man presents with new-onset fever, shortness of breath, lower
More informationtelithromycin oral streptococci 140 telithromycin TEL azithromycin AZM clarithromycin CAM roxithromycin RXM levofloxacin LVFX ampicillin ABPC
telithromycin 3 0 3 0 oral streptococci 0 telithromycintelazithromycin AZMclarithromycinCAMroxithromycinRXMlevofloxacinLVFXampicillinABPC erythromycinem TEL EM erm mef 5 Streptococcus mitis MIC90 ml TEL
More informationMei-lian Wang 1, Ying Zhang 2, Miao Fan 3, Ya-jun Guo 2, Wei-dong Ren 2 and En-jie Luo 1*
Wang et al. Cardiovascular Ultrasound 2014, 12:21 CARDIOVASCULAR ULTRASOUND RESEARCH Open Access Right atrial pressure alterations during echocardiography-guided-catheterization predict tricuspid valvular
More informationaureus."' Previous studies from this laboratory have shown that this agent despite the availability of antimicrobial agents that are effective against
RICHARD E. DIXON* Department of Medicine, JAY S. GOODMAN * * George Vanderbilt Hunter University Laboratory, School of Medicine, M. GLENN KOENIG*** Nashville, Tennessee 3723 LYSOSTAPHIN: AN ENZYMATIC APPROACH
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationOverview. Clinical Scenario. Endocarditis: Treatment & Prevention. Prophylaxis The Concept. Jeremy D. Young, MD, MPH. Division of Infectious Diseases
Endocarditis: Treatment & Prevention Jeremy D. Young, MD, MPH Division of Infectious Diseases Clinical Scenario Patient with MVP scheduled to have wisdom teeth extracted. Has systolic murmur with mid-systolic
More informationANTIBACTERIAL ACTIVITIES OF SELECTED MEDICINAL PLANTS AGAINST MRSA STRAINS ISOLATED FROM SURGICAL WOUND INFECTIONS
ICAMS 2014 5 th International Conference on Advanced Materials and Systems ANTIBACTERIAL ACTIVITIES OF SELECTED MEDICINAL PLANTS AGAINST MRSA STRAINS ISOLATED FROM SURGICAL WOUND INFECTIONS NİZAMİ DURAN
More informationUse of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone
Zurenko et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:46 RESEARCH Open Access Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens
More informationRelationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2004, p. 2398 2402 Vol. 42, No. 6 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.6.2398 2402.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAciphin Ceftriaxone Sodium
Aciphin Ceftriaxone Sodium Only for the use of Medical Professionals Description Aciphin is a bactericidal, long-acting, broad spectrum, parenteral cephalosporin preparation, active against a wide range
More informationEfficacy of Treatment of Staphylococcal Osteomyelitis
ANTIMICROBLAL AGENTS AND CHEMOTHERAPY, Dec. 1992, p. 2693-2697 0066-4804/92/122693-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 12 Relationship between Antibiotic Concentration
More informationExperimental Endocarditis
INFECTION AND IMMUNITY, Dec. 1976, p. 1284-1289 Copyright C 1976 American Society for Microbiology Vol. 14, No. 6 Printed in U.S.A. Effect of Warfarin on the Induction and Course of Experimental Endocarditis
More informationTigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationInfections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)
3 Infections Amenable to OPAT (Nabin Shrestha + Ajay Mathur) Decisions regarding outpatient treatment of infections vary with the institution, the prescribing physician, the individual patient s condition
More informationQ-FEVER Q FEVER. CPMP/4048/01, rev. 3 1/7 EMEA 2002
Q FEVER CPMP/4048/01, rev. 3 1/7 General points on treatment Q fever is a zoonosis caused by Coxiella burnetii, an obligate intracellular gram-negative bacterium with high infectivity but with relatively
More informationSynergism of Fosfomycin-Ampicillin and Fosfomycin-
ANTIMICROBiAL AGENTS AND CHEMoTHERAPY, May 1978, p. 75-79 66-484/78/13-75$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 5 Printed in U.S.A. Synergism of Fosfomycin-Ampicillin and Fosfomycin-
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationUeli von Ah, Dieter Wirz, and A. U. Daniels*
JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 2083 2087 Vol. 46, No. 6 0095-1137/08/$08.00 0 doi:10.1128/jcm.00611-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Rapid Differentiation
More informationThe microbial diagnosis of infective endocarditis (IE)
The microbial diagnosis of infective endocarditis (IE) Pierrette Melin Medical Microbiology pm-chulg sbimc 10.05.2007 1 Introduction for diagnosis Review of microbiological investigation of IE and perspectives
More informationEnhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models
Journal of Antimicrobial Chemotherapy (25) 56, 365 37 doi:.93/jac/dki24 Advance Access publication 7 July 25 Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationBacterial Survival In Synovial Fluid: Is S. aureus in the Knee Joint Persisting Despite Antibiotic Treatment?
Bacterial Survival In Synovial Fluid: Is S. aureus in the Knee Joint Persisting Despite Antibiotic Treatment? Sana Dastgheyb 1, Sommer Hammoud 2, Constantinos Ketonis, MD 3, James Purtill, MD 3, Michael
More informationAnalysis of Rifampin Disk Diffusion and Stability in 7H10 Agar
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1975, p. 187-193 Copyright i 1975 American Society for Microbiology Vol. 8, No. 2 Printed in U.SA. Analysis of Rifampin Disk Diffusion and Stability in 7H1 Agar
More informationScreening of Chinese Medicinal Herbs for the Inhibition of Brucella melitensis
5 th Proceedings of the Seminar in Veterinary Sciences, 5-8 January 2010 Screening of Chinese Medicinal for the Inhibition of Khoo Wen Wen & 1 Siti Khairani Bejo 1 Department of Veterinary Pathology and
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationDAVID M. YAJKO,* CYNTHIA A. SANDERS, JANUSZ J. MADEJ, V. LOUISE CAWTHON, AND W. KEITH HADLEY
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1996, p. 743 749 Vol. 40, No. 3 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology In Vitro Activities of Rifabutin, Azithromycin, Ciprofloxacin,
More informationDiscrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis
Journal of Medical Microbiology (2004), 53, 879 885 DOI 10.1099/jmm.0.45655-0 Short Communication Correspondence Itzhak Brook ib6@georgetown.edu Received 1 March 2004 Accepted 18 May 2004 Discrepancies
More informationTHE USE OF THE PENICILLINASE-RESISTANT
Therapeutic problems THE USE OF THE PENICILLINASE-RESISTANT PENICILLIN IN THE PNEUMONIAS OF CHILDREN MARTHA D. Yow, MARY A. SOUTH AND CHARLES G. HESS From the Department of Pediatrics, Baylor University
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationReceived 10 September 2008/Returned for modification 9 December 2008/Accepted 17 January 2009
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2009, p. 1581 1585 Vol. 53, No. 4 0066-4804/09/$08.00 0 doi:10.1128/aac.01202-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. High
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationActivity of tigecycline alone and in combination with colistin and meropenem against carbapenemase
Activity of tigecycline alone and in combination with colistin and meropenem against carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay Spyros Pournaras, Georgia Vrioni, Evangelia
More informationon June 6, 2018 by guest
JCM Accepts, published online ahead of print on 20 June 2014 J. Clin. Microbiol. doi:10.1128/jcm.01270-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Rothia bacteremia A 10
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More information